NCT07728812Not yet recruiting
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 424 (estimated)
- First submitted
- 10 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Phenomix Sciences
- Diseases
- Obesity
- NCT number
- NCT07728812
What you commit to
- Study type: Interventional
- Planned participants: 424
- From 1 Sept 2026 to the primary completion date, 1 Jul 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No contraindications to the weight loss medications: Phentermine-Topiramate Extended Release (Qsymia®); Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®, Mysimba™); Liraglutide (Saxenda®), Semaglutide (Wegovy®), and Tirzepatide (Zepbound®).
Other
- Pregnancy or currently breast feeding.
Who the study is looking for
- Adults - age 18 or older
- obesity (BMI ≥ 30 kg/m2) without obesity related diseases (ORDs). Or obesity (BMI ≥ 27 kg/m2) with obesity related diseases (ORDs).
- Mayo Clinic employee or dependent
- Referred to Community Internal Medicine Weight Management Program
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.